Physician profile
Stephanie Lufsey
NPI 1174928907
$1,160.67
in general payments reported to CMS, 2019-2025
14 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $181 · 2022: $184 · 2023: $278 · 2024: $235 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.72 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $288.75 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $261.35 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $155.36 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $144.49 | 2021 | |
| Abbvie INC. | $67.49 | 2024-2025 | |
| Exact Sciences Corporation | $50.37 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $47.02 | 2023 | Nuedexta |
| Abbott Laboratories | $36.13 | 2023-2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $32.26 | 2024 | Ajovy |
| Antares Pharma, INC. | $18.62 | 2024 | Xyosted |
| Novartis Pharmaceuticals Corporation | $15.61 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.75 | 2021 | |
| Merck Sharp & Dohme LLC | $14.49 | 2022 | |
| Astellas Pharma US INC | $13.98 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Lufsey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.